JAMA Oncology:癌胚抗原揭示结肠癌风险!

2017-12-27 sunshine2015 来宝网

JAMA肿瘤学杂志12月21日在线发表的一项研究结果显示,结肠癌患者术前癌胚抗原(CEA)水平升高,切除后正常化的风险并不高。

术前正常化的CEA可能帮助预测结肠癌进展】JAMA肿瘤学杂志12月21日在线发表的一项研究结果显示,结肠癌患者术前癌胚抗原(CEA)水平升高,切除后正常化的风险并不高。

纽约纪念Sloan Kettering癌症中心的小西医生和同事们评估了血清CEA水平与结肠癌预后的关系。回顾性分析包括2007年至2014年期间在单个综合癌症中心接受根治性结肠癌切除的1,027例连续结肠癌(I至III期)患者。

研究人员发现,与术前CEA正常的患者相比,术前CEA正常的患者三年无复发生存率(RFS)提高了7.4%(P = 0.01) (P = 0.86)。术后CEA升高的患者RFS较术后CEA正常的患者低14.9%(P = 0.001)。短期RFS与术后CEA升高之间存在独立相关性(危险比[HR] 2.0; 95%可信区间1.1?3.5),但较短的RFS与术后CEA正常化无关(HR 0.77; 95%置信区间,0.45至1.3)。

作者写道:“切除后正常化的术前CEA升高不是预后不良的指标。 “术后CEA升高的患者复发风险增加,尤其是在手术后的头12个月内”。

原始出处:

Tsuyoshi Konishi,Yoshifumi Shimada, Meier Hsu,et al. Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. JAMA Oncol. Published online December 21, 2017. doi:10.1001/jamaoncol.2017.4420.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061701, encodeId=eafe2061e01ec, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Oct 07 18:32:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865257, encodeId=5436186525ebc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 07 15:32:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674437, encodeId=d1c316e44374c, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Mar 10 08:32:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419685, encodeId=080d1419685b7, content=<a href='/topic/show?id=8af1e1542d2' target=_blank style='color:#2F92EE;'>#癌胚抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71542, encryptionId=8af1e1542d2, topicName=癌胚抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d123523167, createdName=lifangping, createdTime=Fri Dec 29 06:32:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623268, encodeId=cb8c1623268e3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Dec 29 06:32:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272976, encodeId=643a2e297683, content=好好看下.内容实在, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Dec 27 18:13:56 CST 2017, time=2017-12-27, status=1, ipAttribution=)]
    2018-10-07 sjq027
  2. [GetPortalCommentsPageByObjectIdResponse(id=2061701, encodeId=eafe2061e01ec, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Oct 07 18:32:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865257, encodeId=5436186525ebc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 07 15:32:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674437, encodeId=d1c316e44374c, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Mar 10 08:32:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419685, encodeId=080d1419685b7, content=<a href='/topic/show?id=8af1e1542d2' target=_blank style='color:#2F92EE;'>#癌胚抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71542, encryptionId=8af1e1542d2, topicName=癌胚抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d123523167, createdName=lifangping, createdTime=Fri Dec 29 06:32:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623268, encodeId=cb8c1623268e3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Dec 29 06:32:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272976, encodeId=643a2e297683, content=好好看下.内容实在, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Dec 27 18:13:56 CST 2017, time=2017-12-27, status=1, ipAttribution=)]
    2018-07-07 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=2061701, encodeId=eafe2061e01ec, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Oct 07 18:32:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865257, encodeId=5436186525ebc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 07 15:32:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674437, encodeId=d1c316e44374c, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Mar 10 08:32:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419685, encodeId=080d1419685b7, content=<a href='/topic/show?id=8af1e1542d2' target=_blank style='color:#2F92EE;'>#癌胚抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71542, encryptionId=8af1e1542d2, topicName=癌胚抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d123523167, createdName=lifangping, createdTime=Fri Dec 29 06:32:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623268, encodeId=cb8c1623268e3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Dec 29 06:32:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272976, encodeId=643a2e297683, content=好好看下.内容实在, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Dec 27 18:13:56 CST 2017, time=2017-12-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2061701, encodeId=eafe2061e01ec, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Oct 07 18:32:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865257, encodeId=5436186525ebc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 07 15:32:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674437, encodeId=d1c316e44374c, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Mar 10 08:32:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419685, encodeId=080d1419685b7, content=<a href='/topic/show?id=8af1e1542d2' target=_blank style='color:#2F92EE;'>#癌胚抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71542, encryptionId=8af1e1542d2, topicName=癌胚抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d123523167, createdName=lifangping, createdTime=Fri Dec 29 06:32:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623268, encodeId=cb8c1623268e3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Dec 29 06:32:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272976, encodeId=643a2e297683, content=好好看下.内容实在, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Dec 27 18:13:56 CST 2017, time=2017-12-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2061701, encodeId=eafe2061e01ec, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Oct 07 18:32:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865257, encodeId=5436186525ebc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 07 15:32:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674437, encodeId=d1c316e44374c, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Mar 10 08:32:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419685, encodeId=080d1419685b7, content=<a href='/topic/show?id=8af1e1542d2' target=_blank style='color:#2F92EE;'>#癌胚抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71542, encryptionId=8af1e1542d2, topicName=癌胚抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d123523167, createdName=lifangping, createdTime=Fri Dec 29 06:32:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623268, encodeId=cb8c1623268e3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Dec 29 06:32:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272976, encodeId=643a2e297683, content=好好看下.内容实在, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Dec 27 18:13:56 CST 2017, time=2017-12-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2061701, encodeId=eafe2061e01ec, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Oct 07 18:32:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865257, encodeId=5436186525ebc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 07 15:32:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674437, encodeId=d1c316e44374c, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Mar 10 08:32:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419685, encodeId=080d1419685b7, content=<a href='/topic/show?id=8af1e1542d2' target=_blank style='color:#2F92EE;'>#癌胚抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71542, encryptionId=8af1e1542d2, topicName=癌胚抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d123523167, createdName=lifangping, createdTime=Fri Dec 29 06:32:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623268, encodeId=cb8c1623268e3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Dec 29 06:32:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272976, encodeId=643a2e297683, content=好好看下.内容实在, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Dec 27 18:13:56 CST 2017, time=2017-12-27, status=1, ipAttribution=)]
    2017-12-27 忠诚向上

    好好看下.内容实在

    0

相关资讯

Seminars in Cancer Biology:饮食重塑肠道微生物功能,降低结肠癌发生风险

饮食在人类健康与代谢中具有重要作用,研究证实饮食对肠道微生物构成和代谢有重大影响,水果、蔬菜和全谷物食物的摄入能减少结直肠癌风险。美国的Seidela教授在Seminars in Cancer Biology杂志上发文,详细介绍了微生物对宿主结直肠癌发生发展的影响,饮食中的活性物质如何通过微生物影响结直肠癌的发生,并提出了许多急待解决的问题及意义。

Brit J Cancer:结肠癌中抑癌基因RHOA失活机制研究

研究证实,结肠癌细胞通过遗传、转录和转录后机制下调抑癌基因RHOA的表达

Health Technol Assess:哪些检测可用于识别结直肠癌患者的Lynch综合征?

2017年9月,发表在《Health Technol Assess》上的一项系统评价和经济学评估,对可用于识别结直肠癌(CRC)患者的Lynch综合征(LS)的分子检测进行了探究。

JAMA Oncology:术前和术后CEA水平与结肠癌预后的关系

临床指南建议检测结肠癌术前CEA水平。术后CEA水平持续升高与肿瘤转移风险增加有关,但是术前升高术后正常的CEA水平的预后作用尚不清楚。JAMA Oncology近期发表了一篇文章,研究术前CEA水平高,术后降至正常的患者是否比术前CEA水平正常的患者复发风险更高。

Colorectal Dis:结肠癌患者的手术治疗——完整结肠系膜切除 vs不完整结肠系膜切除

研究认为,完整结肠系膜切除术可提高手术质量和患者生存率,但患者术后并发症风险增加

Science:细菌会伴随肿瘤的转移而转移!

哈佛大学的科学家们最新发现:结肠癌中的常见细菌,会伴随着肿瘤的转移而转移。而且当采取抗生素对抗这些细菌时,小鼠体内的肿瘤扩散、转移会得到控制。他们推测:这类细菌与肿瘤成功转移有很大的关联性。